Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,833 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

NCT02175121
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Placebo, PF-06291874
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT03510884
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 21, 2026, 9:40 AM EDT
Not listed Phase 2 Interventional

Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders

NCT06503978
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions
MTP-101P, Vancomycin, Miralax, Antacid, Placebo MTP-101P, Placebo Vancomycin
Combination Product
Lead sponsor
Gut-Brain-Axis Therapeutics Inc.
Other
Eligibility
4 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 21, 2026, 9:40 AM EDT
Terminated Phase 2 Interventional Results available

Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C

NCT02971033
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
20mg ezetimibe, Placebo, 40mg ezetimibe
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

NCT03998514
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
CB4211 Dose 1, CB4211 Dose 2, CB4211 Dose 3, CB4211 Dose 4, CB4211 Dose 5, CB4211 Dose 6, CB4211 Dose TBD, Placebo
Drug
Lead sponsor
CohBar, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chula Vista, California • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-In-Human Study of LY3839840 in Healthy Participants

NCT06153355
View directory record Official record
Conditions
Healthy
Interventions
LY3839840, Placebo, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Anaheim, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults

NCT02337855
View directory record Official record
Conditions
Schistosomiasis
Interventions
Placebo, Sm-TSP-2/Alhydrogel, Sm-TSP-2/Alhydrogel/GLA-AF
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

NCT01922921
View directory record Official record
Conditions
HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
HER-2/neu Intracellular Domain Protein, Laboratory Biomarker Analysis, Pertuzumab, Placebo, Polysaccharide-K, Trastuzumab
Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Not applicable Interventional Results available

Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

NCT02598128
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
RELiZORB, Placebo
Device
Lead sponsor
Alcresta Therapeutics, Inc.
Industry
Eligibility
4 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Boise, Idaho • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 21, 2026, 9:40 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

NCT01220128
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers

NCT06879067
View directory record Official record
Conditions
Safety, Tolerability
Interventions
Placebo, Foralumab Nasal
Drug
Lead sponsor
Tiziana Life Sciences LTD
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Results available

Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients

NCT02555371
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab 100mg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Long Beach, California • Riverside, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

NCT04528719
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 79 Years
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
31
States / cities
La Mesa, California • West Hollywood, California • DeLand, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

NCT01370811
View directory record Official record
Conditions
Sialorrhoea
Interventions
oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C, oxybutynin and clonidine oral solution treatment D
Drug
Lead sponsor
Orient Pharma Co., Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bingham Farms, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 21, 2026, 9:40 AM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

NCT07619131
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Laroprovstat, Rosuvastatin 1, Rosuvastatin 2, Laroprovstat/Rosuvastatin 1, Placebo to match rosuvastatin, Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1, Laroprovstat/Rosuvastatin 2, Placebo to match Laroprovstat/Rosuvastatin 2
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
77
States / cities
Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 9:40 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

NCT01900522
View directory record Official record
Conditions
Schizophrenia
Interventions
ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C, ITI-214 Dose D (Elderly), Placebo, ITI-214 Dose E, ITI-214 Dose F, ITI-214 Dose G, ITI-214 Dose H
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Glendale, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

NCT03430661
View directory record Official record
Conditions
Healthy
Interventions
ACT-246475, Clopidogrel, Prasugrel, Placebo, Ticagrelor
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole

NCT00640809
View directory record Official record
Conditions
Bowel Diseases, Inflammatory
Interventions
Celecoxib, Placebo, Ibuprofen plus Omeprazole
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
12
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 21, 2026, 9:40 AM EDT
Terminated Phase 3 Interventional

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

NCT01038739
View directory record Official record
Conditions
Diverticulitis
Interventions
Mesalazine, Placebo
Drug
Lead sponsor
Dr. Falk Pharma GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Smyrna Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study in Subjects With Asthma

NCT00980200
View directory record Official record
Conditions
Asthma
Interventions
Dose 4 QD, Dose 3 QD, placebo, Dose 2 QD, Dose 1 BD
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Cypress, California • Huntington Beach, California • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Not applicable Interventional Results available

Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?

NCT00486902
View directory record Official record
Conditions
Ketamine Adverse Reaction, Effects of; Anesthesia, Spinal and Epidural, in Pregnancy, Complication of Labor and/or Delivery
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Herpes Simplex Type 1 Suppression in Hepatitis C

NCT01580995
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

NCT03385239
View directory record Official record
Conditions
Hypertriglyceridemia, Cardiovascular Diseases
Interventions
ISIS 678354, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Cottonwood, Arizona • Little Rock, Arkansas • Carmichael, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects

NCT04238195
View directory record Official record
Conditions
TQT Study
Interventions
Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo, Moxifloxacin 400mg, Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr), Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Drug · Other
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 21, 2026, 9:40 AM EDT